Lupin launches anti-fungal drug voriconazole in US

Lupin Limited has launched its voriconazole tablet (50 mg & 200 mg) and voriconazole oral suspension (40 mg/mL) having received an approval for these products from the US Food and Drug Administration (FDA) earlier. Voriconazole tablet and oral suspension are generic versions of Vfend tablet and Vfend oral suspension – manufactured by PF Prism CV.

Voriconazole is indicated for use in patients 12 years of age and older in the treatment of the fungal infections. 

According to IMS MAT September 2016, Vfend tablets (50 mg & 200 mg) and oral suspension recorded US sales of $ 81 million and $ 15.2 million, respectively.